Trials / Completed
CompletedNCT06161844
Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
A Phase 3, Randomized, Open-label, Parallel-group, Multicenter, Controlled Study to Evaluate Efficacy and Safety of Semaglutide Injection (HD1916) vs. Ozempic® as add-on to Metformin in Patients With Type 2 Diabetics Mellitus
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 506 (actual)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the similarity of the efficacy and safety of semaglutide injection (HD1916) vs. Ozempic® in patients with type 2 diabetes mellitus (T2DM) with poor blood glucose control after metformin treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | semaglutide injection (HD1916) | Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: HD1916 |
| DRUG | Ozempic® | Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: Ozempic Injectable Product |
Timeline
- Start date
- 2024-02-23
- Primary completion
- 2025-05-14
- Completion
- 2025-05-14
- First posted
- 2023-12-08
- Last updated
- 2025-07-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06161844. Inclusion in this directory is not an endorsement.